Cetuximab is an anti-EGFR antibody that has been shown to improve survival when combined with RT in patients with loco-regionally advanced non-NPC head and neck squamous cell carcinoma (HNSCC) [14]. Here, EGFR is linked to head and neck squamous cell carcinoma.